Skip to Content

Posts tagged with "Toxicology"

  • Clinical Trials

    Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the “up” moments, for sure. The company (in collaboration with Sanofi) has just announced positive Phase 3 data on their therapy for hereditary ATTR amyloidosis – Read More
  • Pharmacokinetics

    Adverse Events: A Look Under the Hood

    As most people know, there’s an FDA Adverse Event Reporting System, which is supposed to capture any sort of problems that turn up with approved drugs. Certainly if you have any kind of job in the industry, you know about it – every corporate training program includes a section about how if you hear about… Read More
  • Cardiovascular Disease

    AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking about anything to do with the response to levels of fuel like glucose or fatty acids and determination of their downstream fates, then AMPK is almost certainly crucial. Activating the enzyme se… Read More
  • Natural Products

    Sodium Benzoate Nonsense

    I don’t spend a lot of time on the blog swatting down idiotic ideas about chemicals. It’s a full time job, and (see next post) I already have a full time job. It’s also frustrating work, because the supply of idiocy is apparently beyond limit, and just when you think you’ve seen the most clueless… Read More
  • Cancer

    How to Know When a New Target is Really a New Target

    This is an excellent article, and the title is self-recommending: “Common Pitfalls in Preclinical Cancer Target Validation”. The abstract speaketh the truth: An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify dr… Read More
  • Cardiovascular Disease

    Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you haven’t been doing this stuff long enough”. Well, it’s pretty hard to hold your breath across a full tox study, but you know what I mean. There are… Read More
  • Life in the Drug Labs

    Pyridine Doesn’t Do What You Think It Does

    OK, this is not exactly a time-sensitive issue, but since I took a crack at one of the most prominent toxicology myths in the biology labs (ethidium bromide is not really all that bad, in case you missed it), I figured I should do the same for one of the persistent myths on the organic… Read More
  • Alzheimer's Disease

    A New Way to Make GSK3 Inhibitors

    Of the discovery of GSK3 (glycogen synthase kinase 3) inhibitors there has been no end. I first came across it as a target it about 1997, and even then, once I started reading the literature, I quickly felt as if I were late to the party. It’s been investigated for diabetes (and other metabolic diseases), Alzheimer’s… Read More
  • Clinical Trials

    Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground up. Well, I have one of those good-news/bad-news reports: it looks like synthetic work will definitely be needed in this area, because the latest clinical candidate in it has… Read More
  • Clinical Trials

    A Quiet And Sudden Exit for Amiselimod

    Here’s an example of a common behavior in this industry – and to be fair, in many others as well. Big deals are celebrated and press-released at the outset, but if things don’t work out, they end very quietly – as quietly as possible. Sometimes that’s not very possible at all, because a big Phase… Read More
123...